What We Covered01:03 – Ed, Brian and Meranda welcome to the show a panel of drug substance services experts, Daniel Torok, Dave Adams, Jim Mencel and David Blasingame who speak to trends they’ve observed in the landscape of API manufacturing 07:04 – The panel speaks to the types of drug manufacturing requests they’ve been seeing 14:42 – The panel expresses their shared concerns over the diminishing number of API manufacturing professionals in the United States 23:53 – The panel provides their thoughts on the immediate future of API manufacturing 30:04 – The panel discusses the current state of regulation 33:15 – Ed, Brian and Meranda thank the panel for joining the showTweetable Quotes“We’re certainly seeing a very rapid change in the API/CMO world. I think if you went out with an RFP maybe two years ago and you threw this RFP out to eight vendors, you’d have eight proposals back fairly rapidly.” “I don’t know how many of you guys have been involved in plant build outs and plant qualifications. It is not a slam dunk, especially when you’re trying to retrofit an existing site.” “The number of people in the U.S. who have manufacturing backgrounds in small molecules is just small and diminishing rapidly because all the jobs have been offshored.” “Good operators are worth their weight in gold.” “I think what has to happen [in the future of API manufacturing in the U.S.] is that the industry has to know that the demand is there.”Relevant LinksDesign Space InPharmatics – LinkedInDesign Space InPharmatics – TwitterEdward Narke on LinkedInDaniel Torok on LinkedInDavid Adams on LinkedInJim Mencel on LinkedInDavid Blasingame on LinkedIn